Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 377,942
  • Shares Outstanding, K 63,201
  • Annual Sales, $ 1,610 K
  • Annual Income, $ -72,630 K
  • 60-Month Beta 3.18
  • Price/Sales 221.52
  • Price/Cash Flow N/A
  • Price/Book 1.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.28
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.30
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.20 +42.38%
on 04/15/19
6.22 -3.86%
on 03/21/19
+0.33 (+5.84%)
since 03/18/19
3-Month
2.90 +106.21%
on 01/30/19
6.22 -3.86%
on 03/21/19
+2.74 (+84.57%)
since 01/18/19
52-Week
2.62 +128.24%
on 11/02/18
7.72 -22.59%
on 08/31/18
-0.55 (-8.35%)
since 04/18/18

Most Recent Stories

More News
Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new preclinical data at...

ADVM : 5.98 (+5.84%)
Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD

- Clinical Hold until Additional CMC Information is Reviewed by FDA -

ADVM : 5.98 (+5.84%)
Report: Developing Opportunities within Adverum Biotechnologies, Aurinia Pharmaceuticals, Baytex Energy, Limelight Networks, Park City Group, and HealthStream -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Adverum Biotechnologies, Inc. (NASDAQ:ADVM),...

AUPH : 6.31 (-0.16%)
BTE : 2.09 (-1.42%)
ADVM : 5.98 (+5.84%)
PCYG : 7.93 (-0.13%)
HSTM : 27.09 (+0.59%)
LLNW : 3.11 (+0.32%)
Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Aaron Osborne, MBBS MRCOphth...

ADVM : 5.98 (+5.84%)
Adverum Biotechnologies to Participate in Upcoming Conferences

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company's participation in several upcoming...

ADVM : 5.98 (+5.84%)
Adverum Biotechnologies (ADVM) Upgraded to Buy: What Does It Mean for the Stock?

Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ADVM : 5.98 (+5.84%)
Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter ended...

ADVM : 5.98 (+5.84%)
Adverum to Present at the Cowen 39th Annual Health Care Conference

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will be participating in the upcoming...

ADVM : 5.98 (+5.84%)
Adverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will be participating in the upcoming...

ADVM : 5.98 (+5.84%)
Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference

-- Data demonstrates long-term expression of ADVM-022, an intravitreally delivered gene therapy currently in phase 1 for wet AMD, does not affect retinal morphology in non-human primates

ADVM : 5.98 (+5.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ADVM with:

Business Summary

Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California.

See More

Key Turning Points

2nd Resistance Point 6.49
1st Resistance Point 6.23
Last Price 5.98
1st Support Level 5.66
2nd Support Level 5.35

See More

52-Week High 7.72
Last Price 5.98
Fibonacci 61.8% 5.77
Fibonacci 50% 5.17
Fibonacci 38.2% 4.57
52-Week Low 2.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar